NEW YORK – Single-cell proteomics firm IsoPlexis said Tuesday it has entered into an exclusive agreement with Swiss life science tools distributor Bucher Biotec.
The agreement will allow Branford, Connecticut-based IsoPlexis to expand sales of its IsoLight and IsoSpark proteomics platforms into Switzerland.
The deal adds to recent agreements IsoPlexis has inked for distribution in countries including Singapore, Malaysia, China, Taiwan, Japan, South Korea, Spain, and Portugal.
"We are excited to partner with Bucher Biotec to further expand the reach of our unique solutions," Peter Siesel, IsoPlexis' chief commercial officer, said in a statement. "Our functional proteomics platform accelerates the development of personalized, curative medicines across a range of diseases and research disciplines. With this partnership, we are excited to see our usership grow even further."
Financial and other terms of the agreement were not disclosed.